Lupus Foundation of America Grants Funds for Pediatric Research in Innovative CAR-Treg Therapy

Transforming Lupus Treatment for Children

The Lupus Foundation of America (LFA) recently unveiled its Pediatric Lupus Research Grant for 2026, focusing on an innovative therapy aimed at children battling lupus. Awarded to Dr. Holly Wobma from Harvard Medical School, the grant is part of the Michael Jon Barlin Pediatric Lupus Research Program. This research aims to explore the potential of CAR-Treg therapy to restore immune balance and achieve disease remission in young patients afflicted with this complex autoimmune disorder.

Lupus poses unique challenges for children, as they often suffer from more severe symptoms and organ involvement compared to adults. With estimates indicating that 10 to 20 percent of lupus cases occur during childhood, the ramifications can be profound, impacting growth and overall quality of life. The LFA initiated the Michael Jon Barlin Pediatric Research Program to honor Michael Jon Barlin, who succumbed to the disease at 24 after battling its severe complications. This program aims to significantly propel research in pediatric lupus treatment and encourage more extensive funding for innovative projects.

Dr. Wobma's study will investigate the therapeutic capabilities of regulatory T cells (Tregs), immune cells that play a crucial role in diminishing inflammation and regulating the immune response. By engineering Tregs with chimeric antigen receptors (CARs), her research seeks to determine whether these modified cells can mitigate inflammation without harming other immune system components. This could fundamentally alter how lupus is treated, particularly in children, and may pave the way for effective cellular therapies which can lead to drug-free remission.

"While current treatments for lupus can manage symptoms and inflammation, they fail to address the root causes within the immune system," noted Dr. Wobma. She emphasizes the importance of finding therapies that can potentially eliminate the chronic burden of lupus for children, allowing them a better quality of life. "The support from the LFA’s Pediatric Research Grant enables me to explore whether CAR-Tregs can provide a much-needed pathway towards these goals."

Joy Buie, Vice President of Research at the LFA, also commented on the significance of this research, stating that CAR cell therapy represents a promising avenue for lupus treatment. However, given its intensive nature and associated risks—especially for younger patients—this study offers hope for a safer alternative that could maintain effective disease management.

The implications of this research extend beyond just immediate treatment benefits. If successful, it could revolutionize pediatric care for lupus, enabling children to live healthier lives free from chronic illness. The pressing need for more substantial research funding has never been more critical, as currently, lupus research is significantly underfunded relative to the disease’s impact. The LFA is committed to changing this narrative, ensuring a brighter future for pediatric lupus patients and their families.

As Dr. Wobma embarks on this essential research journey, the support from the Lupus Foundation signifies a beacon of hope for many families who seek better management and treatment options for their children battling this debilitating disease. By unlocking the potential of CAR-Treg therapy, we stand on the threshold of what could be a groundbreaking shift in pediatric lupus care.

To learn more about the Lupus Foundation of America’s initiatives and how you can contribute, visit lupus.org.